SWOG researchers use cell-free DNA methylation to predict chemo benefit in bladder cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from the SWOG Cancer Research Network used methylation patterns in cell-free DNA extracted from blood samples to predict which patients with muscle-invasive bladder cancer were likely to benefit from chemotherapy before their surgery. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login